



****






Figure 2. Cytotoxicity of compounds **4a-c**, **6a-c**, **8**, **10a-c** and CHS 828 against NUGC, gastric cancer; DLDI, colon cancer; HA22Tand HEPG2, liver cancer; HONEI, nasopharyngeal carcinoma; MCF, breast cancer.


****

Figure 3. Cytotoxicity of compounds **12,** **13**, **14**, **17a-c**, **19**, **20** and CHS 828 against NUGC, gastric cancer; DLDI, colon cancer; HA22T and HEPG2, liver cancer; HONEI, nasopharyngeal carcinoma; MCF, breast cancer.


****

Figure 4. Cytotoxicity ofcompounds **22a-d**, **25a-c** and CHS 828 against NUGC, gastriccancer; DLDI, colon cancer; HA22T and HEPG2, liver cancer; HONEI, nasopharyngeal carcinoma; MCF, breast cancer